Isolated Nodal Failure after Stereotactic Body Radiotherapy for Lung Cancer: The Role for Salvage Mediastinal Radiotherapy

被引:22
作者
Ward, Matthew C. [1 ]
Oh, Steven C. [1 ]
Pham, Yvonne D. [1 ]
Woody, Neil M. [1 ]
Marwaha, Gaurav [2 ]
Videtic, Gregory M. M. [1 ]
Stephans, Kevin L. [1 ]
机构
[1] Cleveland Clin, Taussig Canc Inst, Dept Radiat Oncol, 9500 Euclid Ave,T28, Cleveland, OH 44195 USA
[2] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA
关键词
Nodal failure; SBRT; Salvage; NSCLC; Medically inoperable; RADIATION-THERAPY; LOCOREGIONAL RECURRENCE; LOCAL RECURRENCE; CELL; TRIAL; RESECTION; SURVIVAL; OUTCOMES; TUMORS; NSCLC;
D O I
10.1016/j.jtho.2016.05.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Isolated nodal failure (INF) without synchronous local or distant failure is an uncommon occurrence after stereotactic body radiation therapy (SBRT) for lung cancer. Here we review the natural history and patterns of failure after post-SBRT INF with or without salvage mediastinal radiotherapy (SvRT). Methods: Patients treated with SBRT for non-small cell lung cancer with definitive intent were identified. Patients who experienced hilar or mediastinal INF without synchronous distant, lobar, or local failure were included and grouped according to the use of SvRT. The rates of subsequent locoregional control, distant metastases, progression-free survival (PFS), and overall survival were assessed. Results: Of 797 patients treated with definitive SBRT, 24 (3%) experienced INF and 15 (63%) received SvRT. The most common SvRT regimen (53%) was 45 Gy in 15 fractions. The median follow-up after INF was 11.3 months for survivors. There were no grade 3 or higher toxicities after SvRT. The 1-year Kaplan-Meier PFS and overall survival estimates were 33% and 56% for patients not receiving radiotherapy and 75% and 73% with SvRT. After SvRT, the rate of locoregional control at 1 year was 84.4%. Crude rates of distant failure were 20.0% with SvRT and 22.2% with no radiotherapy. Of the 13 deaths observed, five (38%) were related to distant progression of lung cancer, four (31%) to comorbidities, three (23%) to mediastinal progression, and one (8%) to an unknown cause. Conclusions: INF is uncommon after SBRT. Despite the significant comorbidities of this population, intrathoracic progression remains a contributor to morbidity and mortality. SVRT for INF is well tolerated and may improve PFS. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1558 / 1564
页数:7
相关论文
共 30 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]   Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301) [J].
Atagi, Shinji ;
Kawahara, Masaaki ;
Yokoyama, Akira ;
Okamoto, Hiroaki ;
Yamamoto, Nobuyuki ;
Ohe, Yuichiro ;
Sawa, Toshiyuki ;
Ishikura, Satoshi ;
Shibata, Taro ;
Fukuda, Haruhiko ;
Saijo, Nagahiro ;
Tamura, Tomohide .
LANCET ONCOLOGY, 2012, 13 (07) :671-678
[3]   Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy [J].
Baumann, Pia ;
Nyman, Jan ;
Hoyer, Morten ;
Wennberg, Berit ;
Gagliardi, Giovanna ;
Lax, Ingmar ;
Drugge, Ninni ;
Ekberg, Lars ;
Friesland, Signe ;
Johansson, Karl-Axel ;
Lund, Jo-Asmund ;
Morhed, Elisabeth ;
Nilsson, Kristina ;
Levin, Nina ;
Paludan, Merete ;
Sederholm, Christer ;
Traberg, Anders ;
Wittgren, Lena ;
Lewensohn, Rolf .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3290-3296
[4]  
Bezjak A, 0813 RTOG
[5]   COMPARATIVE SURVIVAL IN PATIENTS WITH POSTRESECTION RECURRENT VERSUS NEWLY DIAGNOSED NON-SMALL-CELL LUNG CANCER TREATED WITH RADIOTHERAPY [J].
Cai, Xu-Wei ;
Xu, Lu-Ying ;
Wang, Li ;
Hayman, James A. ;
Chang, Andrew C. ;
Pickens, Allan ;
Cease, Kemp B. ;
Orringer, Mark B. ;
Kong, Feng-Ming .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (04) :1100-1105
[6]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[7]   SHOULD PATIENTS WITH POSTRESECTION LOCOREGIONAL RECURRENCE OF LUNG-CANCER RECEIVE AGGRESSIVE THERAPY [J].
CURRAN, WJ ;
HERBERT, SH ;
STAFFORD, PM ;
SANDLER, HM ;
ROSENTHAL, SA ;
MCKENNA, WG ;
HUGHES, E ;
DOUGHERTY, MJ ;
KELLER, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 24 (01) :25-30
[8]   A RANDOMIZED TRIAL OF INDUCTION CHEMOTHERAPY PLUS HIGH-DOSE RADIATION VERSUS RADIATION ALONE IN STAGE-III NON-SMALL-CELL LUNG-CANCER [J].
DILLMAN, RO ;
SEAGREN, SL ;
PROPERT, KJ ;
GUERRA, J ;
EATON, WL ;
PERRY, MC ;
CAREY, RW ;
FREI, EF ;
GREEN, MR .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :940-945
[9]  
Edge S.B., 2010, AJCC cancer staging manual, V649
[10]   THE MEDIASTINUM IN NON-SMALL CELL LUNG-CANCER - CT-SURGICAL CORRELATION [J].
GLAZER, GM ;
ORRINGER, MB ;
GROSS, BH ;
QUINT, LE .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1984, 142 (06) :1101-1105